BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 84 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,754 | -65.5% | 4,646 | -9.1% | 0.01% | -65.0% |
| Q2 2023 | $34,033 | -65.6% | 5,110 | -3.6% | 0.02% | -63.0% |
| Q1 2023 | $98,879 | -37.2% | 5,299 | -27.7% | 0.05% | -34.1% |
| Q4 2022 | $157,513 | +17.5% | 7,333 | -35.5% | 0.08% | +54.7% |
| Q3 2022 | $134,000 | -10.1% | 11,365 | +0.7% | 0.05% | -3.6% |
| Q2 2022 | $149,000 | -7.5% | 11,284 | +46.3% | 0.06% | -23.6% |
| Q1 2022 | $161,000 | -3.0% | 7,713 | -5.5% | 0.07% | +14.3% |
| Q4 2021 | $166,000 | -1.2% | 8,164 | +47.1% | 0.06% | -14.9% |
| Q3 2021 | $168,000 | -0.6% | 5,549 | -4.8% | 0.07% | +7.2% |
| Q2 2021 | $169,000 | -39.6% | 5,831 | -10.1% | 0.07% | -41.5% |
| Q1 2021 | $280,000 | -4.8% | 6,486 | +1.9% | 0.12% | -3.3% |
| Q4 2020 | $294,000 | +4.6% | 6,364 | -1.9% | 0.12% | -17.0% |
| Q3 2020 | $281,000 | -28.1% | 6,484 | -12.0% | 0.15% | -20.5% |
| Q2 2020 | $391,000 | – | 7,372 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LUMINUS MANAGEMENT LLC | 157,099 | $4,565,000 | 0.66% |
| ACT CAPITAL MANAGEMENT, LLC | 42,000 | $1,221,000 | 0.63% |
| Knoll Capital Management, LLC | 20,000 | $581,000 | 0.30% |
| Artemis Investment Management LLP | 1,193,290 | $34,664,000 | 0.30% |
| Ghisallo Capital Management LLC | 225,000 | $6,539,000 | 0.25% |
| Monashee Investment Management LLC | 60,000 | $1,744,000 | 0.21% |
| AlphaCentric Advisors LLC | 25,000 | $727,000 | 0.20% |
| CAAS CAPITAL MANAGEMENT LP | 232,285 | $6,750,000 | 0.11% |
| AllSquare Wealth Management LLC | 5,402 | $157,000 | 0.09% |
| CNA FINANCIAL CORP | 9,479 | $275,000 | 0.08% |